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ABSTRACT 
Uropathogenic Escherichia coli (UPEC) is the leading cause of urinary tract 
infections and plays a role in prostatic carcinogenesis and prostate cancer (PCa) 
progression. However, the mechanisms through which UPEC promotes PCa 
development and progression are unclear. Cytotoxic necrotizing factor 1 (CNF1) is 
one of the most important UPEC toxins and its role in PCa progression has never been 
studied. We found that UPEC-secreted CNF1 promoted the migration and invasion of 
PCa cells and PCa metastasis. In vitro studies showed that CNF1 promotes 
pro-migratory and pro-invasive activity through entering PCa cells and activating 
Cdc42, which subsequently induced PAK1 phosphorylation and upregulation of 
MMP-9 expression. CNF1 also promoted pulmonary metastasis in a xenograft mouse 
model through these mechanisms. PAK1 phosphorylation correlated with advanced 
grades of PCa in human clinical PCa tissues. These results suggest that CNF1 derived 
from UPEC plays an important role in PCa progression through activating a 
Cdc42-PAK1 signal axis and upregulating the expression of MMP-9. Therefore, 
surveillance for and treatment of cnf1-carrying UPEC strains may diminish PCa 
progression and thus have an important clinical therapeutic impact. 
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Cdc42; PAK1. 
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Introduction 
Uropathogenic Escherichia coli (UPEC) is the leading cause of urinary tract 
infections (UTIs), accounting for most community (~95%) and hospital acquired 
(~50%) infections [1]. UTIs caused by UPEC can induce cystitis, pyelonephritis and 
prostatitis [2,3]. In addition to being frequently isolated from urine samples of patients 
with cystitis and pyelonephritis, UPEC is also detected in urine, prostatic secretions 
and seminal fluids of patients with prostate cancer (PCa), benign prostatic hyperplasia 
(BPH) and prostatitis [4,5].  
PCa is one of the most common cancers in the western world [6]. In the United 
States, approximately 2.8 million men are diagnosed with PCa each year, which 
represents 4 in 10 male cancer survivors and 1 in 5 of all cancer survivors [7]. In 2016, 
it is estimated that there will be 180,890 new PCa cases and 26,120 PCa-related 
deaths in the United States, resulting in PCa as being the most common form of 
cancer (21%) and ranking as the second most frequent cause of cancer-related death 
(8%) [8]. Although PCa is not the most common cancer in China, its incidence and 
mortality rates are rapidly increasing [9]. The five-year relative survival rate for 
localized PCa is very high; however, it is low for men with advanced PCa [8]. 
UPEC infection of male C3H/HeOuJ mice results in prostatic intraepithelial 
neoplasia (PIN) at 12 weeks, and high-grade prostate dysplasia and invasive PCa 26 
weeks after infection [10]. UPEC can accelerate prostatic carcinogenesis induced by 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a dietary carcinogen, and 
reduces the survival of rats [11]. Pro-oncogenic epithelial changes were found in the 
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prostates of C57BL/6J mice 8 weeks post-infection with UPEC [12]. In the 
genetically engineered Hi-Myc murine PCa model, significantly more UPEC-infected 
mice had invasive cancer compared to saline-treated mice [12].  
Cytotoxic necrotizing factor 1 (CNF1) is a key UPEC toxin. After binding to the 
surface of epithelial cells, CNF1 is internalized by endocytosis and subsequently 
transferred to an endosomal compartment, resulting in the enzymatic domain of CNF1 
being translocated into the cytoplasm [13,14]. CNF1 induces deamidation of specific 
glutamine residues of several Rho GTPases including RhoA, Rac1 and Cdc42, 
resulting in their activation and cell motility [15-18]. The cnf1 gene can be detected in 
UPEC strains isolated from patients with prostatitis and in tissue samples of BPH 
[3,19,20]. The prevalence of cnf1 in UPEC strains from prostatitis samples is higher 
than that of samples from cystitis and pyelonephritis [5]. It has also been reported that 
the prevalence of E. coli strains harboring cnf1 is higher in biopsies of patients with 
colorectal cancer than patients with diverticulosis, which implies a role of CNF1 in 
cancer [21]. 
In this study, we investigated the role of CNF1 in the motility and invasiveness of 
PCa cells and PCa metastasis and explored the signaling mechanisms through which 
CNF1 achieved its activity in PCa progression. 
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Materials and Methods 
Cell lines and reagents 
The sources of cell lines and reagents are as follows: PC3, LNCaP, 22Rv1 and VCaP 
(ATCC, Manassas, VA), the Cdc42 inhibitor CID44216842, RhoA inhibitor 
CCG-1423, and PAK1 inhibitor IPA3 (SML0918, SML0987 and I2285, 
Sigma-Aldrich, St. Louis, MO), the Rac1 inhibitor EHT 1864 (HY-16659, MedChem 
Express, New Jersey, USA).  
Bacterial strains and plasmids 
The bacterial strains and plasmids used in this study are listed in Table S1. All strains 
were grown at 37°C in Luria-Bertani (LB) medium for 12 h. When antibiotics were 
required, they were used at the following final concentrations: kanamycin at 50 μg/ml, 
ampicillin at 100 μg/ml. The cnf1 gene from UPEC strain 1 and 11 were amplified by 
PCR and cloned into pET-28a(+) or pTRC99A. The cDNAs coding for Cdc42 or 
PAK1 were subcloned into pCMV-Myc or pEGFP-N1. The constructed plasmids and 
primer sequences are listed in Tables S1 and S2. 
CNF1 recombinant protein expression and purification 
CNF1 was purified as previously described [16]. The purified protein was also 
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identified by LC-MS/MS: The corresponding band was excised and subjected to 
in-gel digestion. Resulting peptides were separated by reverse phase liquid 
chromatography on an easy-nLC 1000 system (ThermoFisher Scientific, Waltham, 
MA, USA) and directly sprayed into a Q-Exactive mass spectrometer (ThermoFisher). 
All MS/MS spectra were searched against the Uniprot-ecoli protein sequence database 
using the PD search engine (version 2.1.0, ThermoFisher) with an overall false 
discovery rate (FDR) for peptides of less than 1%. 
Mutagenesis 
Mutagenesis of cnf1, CDC42 and PAK1 were performed by a round circle polymerase 
chain reaction-based site-directed Fast Mutagenesis System kit (TransGen Biotech, 
Beijing, China) according to the manufacturer’s protocol. The primers used for 
mutation were WQ0434 to WQ0437, WQ0465-2 to WQ0468 and WQ0561 to 
WQ0568 (Table S2).  
Wound healing assay 
PC3 were grown to 95%-100% confluency and wounds generated with a 200 μL 
pipette tip, and treated with buffer, LPS or CNF1 (1 nMol/L). Images of wound 
healing were taken at the indicated time intervals using a microscope (Leica 
Microsystems, Wetzlar, Germany). The wound area was measured by Image J 
software.  
Transwell migration and invasion assay 
Cell migration and invasion assays were performed using Transwell chambers (pore 
size of 8 μm, Costar, Corning 3422), with Corning Matrigel Matrix (Corning 
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Incorporated, Corning, NY, USA) for invasion assays. The inserts were placed in 
24-well culture plates. Cells were resuspended in serum-free RPMI 1640 medium. 
PC-3 cells (2 × 105 in 200 μl) were added to the upper chamber of uncoated (for 
migration assays) or Matrigel coated (for invasion assays) membranes with CNF1 (1 
nMol/L), LPS, or buffer. 600 μL of medium containing 20% fetal bovine serum with 
CNF1 (1 nMol/L), LPS or buffer was added to the lower chamber as chemoattractant. 
After 12 h (migration assays) or 24 h (invasion assays) incubation at 37°C in a 5% 
CO2 humidified atmosphere, the cells that had not migrated through the pores were 
manually removed from the upper face of the filters using cotton swabs, and cells 
adherent to the bottom surface of the inserts were fixed in 4% paraformaldehyde for 1 
h and stained with 0.1% crystal violet (Beijing Solarbio Science & Technology Co., 
Ltd., Beijing, China) for 15 min. Finally the filters were washed three times in PBS 
and images taken under a microscope (Leica Microsystems) with 200 × 
magnification.  
Immunofluorescence analysis 
Cells were grown on glass coverslips, fixed with 4% paraformaldehyde for 15 min 
and blocked with phosphate-buffered saline (PBS) containing 10% goat serum for 60 
min. Cells were incubated with CNF1 antibody (Santa Cruz Biotechnology, Santa 
Cruz CA, USA, sc-52655, 1:200) in PBS at 4°C overnight, washed three times with 
PBS, incubated with Alexa Fluor 488-labeled secondary antibody (Life Technologies, 
Gaithsburg MD, USA) in PBS for 1 h and analyzed using a confocal fluorescence 
microscope (FV1000-D, Olympus, Tokyo, Japan). 
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Rho GTPase activation assays 
PC3 cells were seeded in 10 cm dishes. After treatment, Cdc42- , Rac1- and RhoA- 
activation were measured using the respective Activation Assay Biochem Kit (Cdc42: 
BK034; Rac1: BK035; RhoA: BK036, Cytoskeleton, Dencer CO, USA) according to 
the manufacturer’s protocol. 
Antibodies and western blotting 
Antibodies were obtained from the following companies: anti-Phospho-PAK1 
(Thr423) (#2601, 1:1000), anti-PAK1 (#2602, 1:1000) from Cell Signaling 
Technology, Danvers MA, USA; anti-MMP2 (sc-10736, 1:500), anti-CNF1(sc-52655, 
1:500) from Santa Cruz; anti-MMP9 (PB0709, 1:500) from BOSTER WuHan, China). 
Cells were washed by PBS three times after treatment with CNF1 or dialysis buffer. 
Whole cell lysates were prepared using RIPA lysis buffer (Millipore Billerica, MA, 
USA), adding complete protease inhibitors and phosphatase inhibitors (Roche, Basel, 
Switzerland). Protein concentration was determined using the BCA Protein Assay Kit 
(ThermoFisher) and approximately 40 µg of cell lysates were used. Antibody binding 
was revealed using an HRP-conjugated anti-rabbit IgG or anti-mouse IgG 
(Sigma-Aldrich). Antibody complexes were detected using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) and exposure to Tanon-5200 machine. 
Densitometry was performed using Image J software.  
Transduction and transfection 
PC3 or 22Rv1 cells stably expressing luciferase were constructed using lentiviral 
supernatant and selected with puromycin following the manufacturer’s instructions. 
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PC3-luci cells stably expressing CNF1 or CNF1-C866S (AA 515-1014) were 
constructed using lentiviral supernatant. PC3 and 22Rv1 cells were transiently 
transfected with the Cdc42 and PAK1 related plasmids using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). 
Tumor xenograft model 
Male NOD/SCID mice were purchased from Academy of Military Medical Science 
(Beijing, China). All mouse studies were approved by the Animal Ethics Committee 
of Tianjin Medical University. All animals were 6-8 weeks of age at the time of 
injection. PC3 cells, expressing luciferase or CNF1 or CNF1-C866S, were 
resuspended in 300 μl PBS (Biological Industries) and injected into the lateral tail 
vein of mice (2 × 106 cells/animal). 22Rv1-luci cells treated with CNF1 or 
CNF1-C866S (1 nMol/L for 12 h) were resuspended in 50% matrigel and injected into 
the prostate of mice (4 × 106 cells/animal).  
Mice of both groups were imaged weekly using an IVIS Spectrum scanner (Caliper 
Life Sciences, Alameda, CA, USA). 200 μl of substrate D-luciferin (Promega 
MadisonWI USA) (3.0 mg) in PBS was injected i.p. in each mouse 10 min prior to 
imaging. The bioluminescence images were quantified by measuring the total photons 
over the body and presented as photons/second /cm2 /sr (sr denotes steradian). 
Immunohistochemistry (IHC) 
Murine lungs were fixed in 4% paraformaldehyde for 24 h and processed for paraffin 
embedding. Sections (5 μm) were used for hematoxylin and eosin staining and 
immunohistochemistry for HLA class I (HLA-A, 1:200, 15240-1-AP, Proteintech, 
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Chicago, IL, USA), p-PAK1 (Thr423) (1:10, #2601, Cell Signaling Technology) and 
MMP-9 (1:100, BA0573, BOSTER). 
RNA interference 
Double-stranded RNAs as siRNAs for targeted genes and Scrambled siRNA (siScr) 
were synthesized by GenePharma (Shanghai, China). The sequences (sense strand) of 
siRNAs are listed in Table S2. Specific gene knockdowns were assessed by western 
blotting. Transfection of siRNA was carried out using Lipofectamine 3000 
(Invitrogen).  
Tissue microarray analysis 
The prostate cancer tissue microarray (PR1921a) containing 96 male specimens (8 
normal prostate tissue, 8 adjacent normal prostate tissues, and 80 malignant tissues 
with grade II, II-III or III) was purchased from Alenabio (Xi'an, China). Staining was 
evaluated as described previously [22], and the values of staining intensity were 
determined by Image-Pro Plus software. 
Statistical analyses 
Data from three independent experiments are presented as the mean ± SD. The 
statistical significance of differences between groups was calculated using two-tailed 
student’s t-test or one-way analysis of variance using SPSS 22.0 software. 
Phylogenetic analysis 
The presence of cnf1 was found by screening the genome sequences of 63 UPEC 
strains used in our previous study [23]. A phylogenetic tree based on the alignments of 
combined protein sequences from CNF1 was constructed using maximum likelihood 
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in MEGA 5 with 1000 bootstrap experiments. 
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Results 
CNF1 promotes the migration and invasion of prostate cancer cells in vitro 
Recombinant CNF1 derived from UPEC strain 11 was purified and validated using 
mass-spectrography (Table S3). PC3 cells were treated with CNF1, LPS or the 
dialysis buffer as control and then subjected to a wound healing assay. CNF1 induced 
migration in a dose- and time-dependent manner (Figure 1A, B). Promotion of PC3 
migration and invasion by CNF1 was also evaluated in a transwell assay (Figure 1C, 
D). We further validated the pro-migratory and pro-invasive effects of CNF1 on other 
androgen-dependent or -independent PCa cell lines (LNCaP, VCaP and 22Rv1) 
(Figure S1A, B). As CNF1 is a typical secretory bacterial protein, we treated PC3 
cells with the supernatant from CNF1-overexpressing E. coli K12, which increased 
both the migration and invasion abilities of PC3 cells (Figure 1E, F).  
It has been reported that cysteine 866 and histidine 881 are functional essential 
amino acid residues of CNF1 [24]. C866S mutation completely eliminated CNF1’s 
pro-migratory and pro-invasive effects, while H881Q partially blocked activity 
(Figure 1G, H and Figure S1C). Taken together, these results provide strong evidence 
that CNF1 has pro-migratory and pro-invasive activity on PCa cells. 
CNF1 promotes the in vivo metastasis of prostate cancer cells  
The effect of CNF1 on metastasis of PC3 cells was analyzed in vivo using a xenograft 
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mouse model. PC3 cells were transduced with constitutively expressed luciferase and 
the CNF1 functional domain (named CNF1c, AA 515 to 1014, the functional fragment 
previously reported [14]), or CNF1c-C866S, or a luciferase only control. 
The expression of luciferase, CNF1c and CNF1c-C866S was confirmed in the 
transduced cells. Overexpression of CNF1c protein but not CNF1c-C866S promoted 
migration and invasion (Figure S2A-C). Control or CNF1c-expressing or 
CNF1c-C866S-expressing PC3 cells were injected into the tail vein of NOD/SCID 
mice. Three weeks after injection, mice receiving the PC3 cells with CNF1c 
overexpression had a higher level of lung metastasis compared to mice receiving the 
PC3 cells with either CNF1c-C866S or control vector (Figure 2A and Figure S2D). 
Lung metastasis in mice receiving the CNF1c-overexpressing PC3 was identified by 
H&E staining and by IHC for HLA (Figure 2B, C).  
Luciferase labeled 22Rv1 cells treated with CNF1 or CNF1-C866S were injected 
into the prostate of NOD/SCID mice. Seven weeks after injection, mice receiving 
22Rv1-luci cells treated with CNF1 had a higher level of metastasis (Figure 2D and 
Figure S2E). 
CNF1 activates Rho GTPases in prostate cancer cells 
To determine whether CNF1 can enter PCa cells, we treated PC3 cells with CNF1 for 
12 h and performed immunofluorescence (IF) for CNF1 protein. There was 
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accumulation of CNF1 protein in the cytoplasm (Figure 3A). We also verified the 
intracellular presence of CNF1 using western blotting (Figure 3B).  
We examined the activation levels of the main three Rho-GTPase family members, 
(RhoA, Cdc42 and Rac1) induced by CNF1 using a pull down assay. RhoA, Cdc42 
and Rac1 were activated in PC3 cells treated by CNF1; and among the three GTPases, 
CNF1’s affect was stronger on Cdc42 and Rac1 compared to RhoA (Figure 3C-E).  
CNF1 promotes the migration and invasion of prostate cancer cells through 
Cdc42 
We hypothesized that CNF1 promoted the motility and invasive properties of PCa 
cells by activating Rho GTPases, which regulate actin cytoskeletal re-arrangement 
[25]. We blocked the three GTPases using inhibitors (Figure S3A) and found that 
enhancement of motility and invasion by CNF1 was attenuated in a dose-dependent 
manner by inhibiting Cdc42, but not Rac1. Inhibition of RhoA reduced PC3 migration 
and invasion in both the CNF1 treated and control groups (Figure 4A-F). 
Cdc42 expression was knocked down using siRNAs (Figure 4G, Figure S3B). The 
migration and invasion of Cdc42 knocked-down PC3 cells treated with CNF1 was 
significantly diminished compared to siScr control (Figure 4H, I). Two other siRNAs 
targeting different sites of Cdc42 were used to verify our observations (Figure S3C, 
D). RhoA and Rac1 were also knocked down using siRNA, which did not affect the 
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migration and invasion of PC3 cells promoted by CNF1 (Figure S3E-J). 
The activation level of Cdc42 in the androgen-dependent cell line 22Rv1 was also 
up-regulated after treatment of CNF1 (Figure S3K). To determine the role of active 
Cdc42 in the migration and invasion of PCa cells, Cdc42 or constitutively active 
Cdc42 (CA-Cdc42, Q61E; Q61 was reported to be deamidated by CNF1 [17]) or 
dominant negative Cdc42 (DN-Cdc42, T17N) were transfected into PC3 
(androgen-independent) or 22Rv1 (androgen-dependent) cells. PCa cells transfected 
with CA-Cdc42 had higher levels of active Cdc42 and their migration and invasion 
ability were significantly increased compared to PCa cells transfected with Cdc42 or 
DN-Cdc42 (Figure 4J-L, Figure S4A-C).  
Cdc42-mediated phosphorylation of PAK1 is essential for the enhancement of 
prostate cancer cell migration and invasion induced by CNF1 
Group I p21-activated kinase 1 (PAK1) is an important effector of the small GTPase 
Cdc42 [26], and acts as an important regulator of cytoskeletal dynamics and cell 
motility [27]. To determine pro-migratory and pro-invasive effects of CNF1 on PC3 
cells, we blocked this pathway with the PAK1 inhibitor (IPA3) [28]. Exposure of 
CNF1-treated PC3 cells to IPA3 decreased their migration and invasion in a 
dose-dependent manner (Figure 5A, B), indicating that CNF1 promotes these 
activities through PAK1. Thr423 phosphorylation is required for full activation of 
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PAK1 [28] and we found elevated phosphorylation of PAK1 at Thr423 after treatment 
with CNF1 (Figure 5C). Elevated phosphorylation of PAK1 was also identified in 
22Rv1 cells treated with CNF1 (Figure 5D). 
To determine the role of PAK1 phosphorylation in the migration and invasion of 
PCa cells, PAK1 or constitutively active PAK1 (CA-PAK1, T423E) or dominant 
negative PAK1 (DN-PAK1, K299R) were transfected into PC3 and 22Rv1 cells. The 
migration and invasion ability of PCa cells transfected with CA-PAK1 were 
significantly increased compared to PCa cells transfected with PAK1 or DN-PAK1 
(Figure 5E-G, Figure S5A-C). 
As we identified that CNF1 mediates its activity, in part, through Cdc42, we next 
investigated whether PAK1 activation is directly mediated by Cdc42 activation. The 
Cdc42 inhibitor CID44216842 inhibited phosphorylation of PAK1 (Figure 5H), and 
increased PAK1 phosphorylation was found in PC3 and 22Rv1 cells transfected with 
CA-Cdc42 compared to those transfected with Cdc42 or DN-Cdc42 (Figure 4J, Figure 
S4A). These findings demonstrate that CNF1 activates Cdc42-PAK1 signaling to 
promote the migration and invasion of prostate cancer cells. 
CNF1 upregulates the expression of MMP-9 by activating PAK1 
Nearly every member of the matrix metalloproteinases (MMPs) family has been 
reported to be dysregulated in human cancers, with the gelatinases (MMP-2 and 
MMP-9) playing a pivotal role in degrading extra-cellular matrix (ECM) [29]. We 
explored whether the pro-invasive effect is associated with MMP-9 or MMP-2. CNF1 
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upregulated MMP-9, but had no effect on MMP-2 expression. PAK1 inhibition 
diminished the ability of CNF1 to upregulate MMP-9 (Figure 6A). Increased MMP9 
was found in PC3 and 22Rv1 cells transfected with CA-PAK1 compared to PCa cells 
transfected with PAK1 or DN-PAK1 (Figure 5E, Figure S5A). These results 
demonstrate that CNF1 can upregulate the expression of MMP-9 by activating PAK1. 
Inhibition of Cdc42 also significantly reduced the expression of MMP-9, but not of 
MMP-2 (Figure 6B). The level of active Cdc42, PAK1 phosphorylation and MMP-9 
expression were also upregulated in PC3 cells with CNF1c overexpression compared 
to those with CNF1c-C866S or the control vector (Figure S2F). These results 
demonstrate that CNF1 can drive migration and invasion of PCa cells through the 
Cdc42-PAK1-MMP-9 pathway in vitro.  
To further validate the role for CNF1 in promoting PCa invasion through PAK1 and 
MMP-9, we performed IHC analysis of lung tissue from the experimental mice 
described previously. MMP-9 and phosphorylated PAK1 expression were present in 
pulmonary metastasis of mice injected by PC3 cells with CNF1c expression (Figure 
6C). These results suggest a key role for the Cdc42-PAK1-MMP-9 signaling axis in 
CNF1-induced PCa aggressiveness in vivo. 
Activation of PAK1 is positively correlated with advanced human prostate 
cancer 
The expression of phosphorylated PAK1 was analyzed by IHC using a human tissue 
array containing 96 samples, which include 80 PCa tissues with grade II, II-III, or III. 
The percentage of samples with phosphorylated PAK1 staining in malignant tissues 
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was higher than those in normal and adjacent normal tissues and was positively 
correlated with the histological grades of PCa (Figure 6D, E). We also found that the 
levels of phosphorylated PAK1 were strongly correlated with PCa grades (Figure 6F), 
and the positive percentage of samples with strong staining was higher in grade III 
and II-III than in grade II (Figure 6G). These results indicate that PAK1 activation is 
correlated with PCa advanced grades. 
CNF1 derived from other UPECs has similar pro-migratory and pro-invasive 
effects on prostate cancer cells 
We found 11 of 63 UPEC strains with available genome sequences included the cnf1 
gene. The 11 CNF1 proteins were separated into two groups, with two different amino 
acids (N666T, V1001A) in the segment of 515-1014 (Figure S6A). We purified 
another recombinant CNF1 derived from the UPEC strain 1, which belongs to a 
different UPEC group than the UPEC strain 11. Consistent with the results obtained 
from the UPEC strain 11-derived CNF1, UPEC strain 1-derived CNF1 also promoted 
the migration and invasion of PC3 cells (Figure S6B, C). Additionally, we detected 
the effects of Cdc42, Rac1, RhoA, and PAK1 inhibitors on strain 1-derived 
CNF1-induced cell migration and invasion (Figure S6D, E). The changes of MMP-9 
expression and PAK1 phosphorylation level induced by CNF1 (strain 1) were also 
examined using western blotting (Figure S6F).  
Three UPEC strain 11-derived CNF1 mutants: N666T, V1001A and double mutant 
were created. Wildtype and mutant CNF1-overexpressed E. coli K12 were used to 
perform phenotype experiments, and no obvious difference was observed on PC3 cell 
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migration and invasion (Figure S6G-I). These findings demonstrate that CNF1 
derived from other UPECs has similar pro-migratory and pro-invasive effects on 
prostate cancer cells and that residues 666 and 1001 do not influence CNF1 activity.  
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Discussion 
In this study, we identified that CNF1 secreted by UPEC could accelerate PCa 
progression through activating the Cdc42-PAK1 signaling axis (Figure S7). Almost 20% 
of all cancers are associated with microbial infection [30], and certain cancer types are 
promoted by bacteria. Helicobacter pylori is a prime example that bacterial pathogens 
can drive carcinogenesis, and has been classified as a carcinogen for gastric cancer by 
the International Agency for Research on Cancer (IARC) [31,32]. Other pathogenic 
bacteria such as Salmonella enterica, Borrelia burgdorferi, Chlamydia psittaci and 
Staphylococccus aureus have been reported to be associated with gallbladder cancer 
and certain kinds of lymphomas [33-37]. A few bacterial virulence factors have been 
identified to promote cancer by interacting with human signaling pathways, such as 
CagA and VacA of H. pylori and SEA of S. aureus [36,38]. The possible roles for 
many other bacterial toxins on cancer development and progression remain to be 
clarified. 
Cdc42 expression is upregulated in many kinds of cancers such as breast, colorectal 
and ovarian cancer [39,40]. The role of Cdc42 in prostate cancer is rarely reported. 
The p21-activated kinases (PAKs) are overexpressed and activated in many human 
cancers and are positively correlated with advanced grades and decreased survival, 
and PAK1 is one of the best characterized PAKs dysregulated in cancers [41]. PAK1 
upregulates MMP expression in breast cancer cells [42]. Higher expression of PAK1 
was found in invasive PCa cells compared to non-invasive PCa cells, and inhibition of 
PAK1 impaired PC3 cell migration [43]. It was suggested that this effect was caused 
This article is protected by copyright. All rights reserved.
 23 
 
by high expression of MMP-9 and low expression of TGF²  regulated by PAK1 [43]. 
In our study, CNF1 increased the phosphorylation of PAK1 by activating Cdc42, and 
then upregulated the expression of MMP-9. Upregulation of active PAK1 correlated 
with advanced-grade PCa using clinical human PCa samples, indicating that active 
PAK1 is a possible marker, although further experiments are required. 
Only UPEC strains CP1 or CP9 have been used to infect the prostate in mouse or 
rat models in previous reports [11,12,44]. In our study, UPEC strain 1 or 11 cannot 
successfully infect the prostate of NOD/SCID mice and C57BL/6J mice, indicating 
that UPEC strains used for prostate infection in mouse models are very limited. CNF1 
has been reported to enhance inflammation in bladder and prostate [44,45], and we 
also found that bladder inflammation caused by the CNF1 overexpressing K12 stain 
was greater than that caused by the CNF1 C866S overexpressing K12 stain and the 
K12 control strain (data not shown). Therefore, in addition to migratory and invasive 
activity of PCa cells promoted by CNF1, CNF1 inducing inflammation may also 
promote PCa progression, which needs further studies. 
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Figure legends 
Figure 1. CNF1 promotes the migration and invasion ability of PCa cells. (A) 
This article is protected by copyright. All rights reserved.
 28 
 
Migration ability in the wound healing assay of PC3 cells treated with recombinant 
CNF1 protein in different doses, dialysis buffer and LPS as the control. (B) Time 
dependent migration assay of CNF1 (1 nMol/L) on PC3 cells. (C) and (D) Transwell 
based migration and invasion assays of PC3 cells treated with 1 nMol/L CNF1. (E) 
and (F) Migration and invasion assays of PC3 cells treated with supernatant from 
overexpressed CNF1 or vector in E. coli K12. (G) and (H) Migration and invasion 
assays of PC3 cells treated with supernatant from different strains overexpressing 
wild type CNF1 and CNF1 mutant C866S or H881Q (blank vector as the negative 
control). Bar graphs represent data from three independent assays (mean ± SD. **p < 
0.01; one-way ANOVA (A-D, G and H) or Student’s t test (E and F). Scale bar, 50 
μm. 
 
Figure 2. CNF1 promotes the in vivo metastasis of prostate cancer cells in a xenograft 
mouse model. (A) Luciferase labeled PC3 cells without CNF1 expression (N = 9), 
with CNF1 expression (N = 12) or with CNF1-C866S expression (N = 7) (2 × 106) 
were injected into NOD/SCID mice via the lateral tail vein, and bioluminescence 
imaging of live mice was performed at the third week. (B) H&E staining of lung 
tissue showing significant metastasis in the CNF1 group (magnification 100× and 
400×) and normal tissue in the control group. (C) Immunohistochemically analysis of 
murine lung with PC3 cells staining HLA-A with a specific antibody (magnification 
100× and 400×). (D) Luciferase labeled 22Rv1 cells treated with CNF1 (N = 4), or 
CNF1-C866S (N = 6) (4 × 106) were injected into the prostate of NOD/SCID mice, 
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and bioluminescence imaging of live mice was performed at the seventh week.  
 
Figure 3. CNF1 activates Rho GTPases in PCa cells. (A) Representative 
immunofluorescence images of PC3 cells treated with recombinant CNF1 protein (1 
nMol/L) for 12 hours. Blue, nucleus; Green, CNF1. Scale bar, 50 μm. (B) Western 
blotting analysis of CNF1 protein in PC3 cells cultured with CNF1 recombinant 
protein (1 nMol/L) for 3 and 6 hours, ² -actin as the loading control. (C–E) Western 
blotting analysis of activated Rho GTPases. RhoA, Cdc42 and Rac1 in PC3 cells 
(treated with recombinant CNF1 protein (1 nMol/L) or dialysis buffer for 12 hours) 
after immunoprecipitation with GTP-pull down assays using specific antibodies.  
 
Figure 4. CNF1 promotes the migration and invasion of PCa cells through Cdc42. (A–
C) Transwell migration assays of PC3 cells treated with specific inhibitors of RhoA 
(CCG-1423), Cdc42 (CID44216842) and Rac1 (EHT 1864) in different 
concentrations and 1 nMol/L CNF1 (or dialysis buffer). Line graphs represent data 
from 3 independent assays. (D–F) Invasion assays of PC3 cells treated with specific 
inhibitors for Rho GTPases with CNF1 protein. (G) Western blotting analysis of PC3 
cells treated with siRNAs targeting Cdc42 and scrambled non-targeting control 
siRNA. (H) and (I) Migration and invasion assays of CNF1 treated PC3 cells after 
being transfected with Cdc42 or scramble siRNAs. (J) Western blotting analysis of 
PC3 cells transfected with Vector, Cdc42, constitutively active Cdc42 or dominant 
negative Cdc42. (K) and (L) Migration and invasion assays of PC3 cells transfected 
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with Vector, Cdc42, constitutively active Cdc42 or dominant negative Cdc42. Bar 
graphs represent data from three independent assays (mean ± SD. *p < 0.05. **p < 
0.01; one-way ANOVA (A to F, H, I, K and L). Scale bar, 50 μm. 
   
Figure 5. Cdc42-mediated phosphorylation of PAK1 is essential for the enhancement 
of PCa cell migration and invasion by CNF1. (A) Migration assays of PC3 cells 
cultured with the PAK1 inhibitor IPA3 in different concentrations accompanied with 
CNF1 protein or dialysis buffer. Line graph represents data from three independent 
experiments. (B) Invasion assays of PC3 cells under the treatment of IPA3 and CNF1, 
DMSO and dialysis buffer as the specific control. The bar graph represents data from 
three independent assays. (C) Western blotting analysis of activated PAK1 
(phosphorylated on Thr423) and total PAK1 in PC3 cells after the treatment with 
CNF1 protein (1 nMol/L) at 3-12 hours. (D) Western blotting analysis of 22Rv1 cells 
treated with CNF1 or dialysis buffer. (E) Western blotting analysis of PC3 cells 
transfected with Vector, PAK1, constitutively active PAK1 or dominant negative 
PAK1. (F) and (G) Migration and invasion assays of PC3 cells transfected with Vector, 
PAK1, constitutively active PAK1 or dominant negative PAK1. (H) Analysis of 
activated PAK1 and total PAK1 of PC3 cells under the treatment of the Cdc42 
inhibitor CID44216842 and CNF1 protein, with DMSO and dialysis buffer as the 
control. Bar graphs represents data from three independent assays (mean ± SD. *p < 
0.05. **p < 0.01; one-way ANOVA (A, B, F, G). Scale bar, 50 μm.  
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Figure 6. CNF1 upregulates the expression of MMP9 through Cdc42-PAK1 axis and 
active PAK1 are positively correlated with advanced-grade PCa. (A) and (B) Western 
blotting analysis of metastasis associated metalloproteinases MMP-9 and MMP-2 in 
PC3 cells treated with the PAK1 inhibitor IPA3 or the Cdc42 inhibitor CID44216842 
with CNF1 protein or dialysis buffer. (C) IHC of murine lung specimens from 
CNF1-overexpressed PC3 xenograft metastasis model for MMP-9 and activated 
PAK1 (magnification 100× and 400×). (D) IHC analysis of PAK1 phosphorylation 
using human PCa tissue microarray. Representative images (magnification, 200×) 
from normal prostate tissues, adjacent normal prostate tissues, and malignant prostate 
tissues with grade II, II-III or III are shown. (E) The percentage of samples with 
positively stained p-PAK1. n indicates the sample size in different groups. (F) Mean 
intensity of staining determined by Image-Pro Plus software and presented with box 
plots. (G) The percentage of samples with high (orange), medium (dark gray) and 
weak (light gray) staining of p-PAK1 in positively stained samples with different 
grades. Data are mean ± SD. *p < 0.05. **p < 0.01; one-way ANOVA (A, B, F). 
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